In two studies published concurrently, Pal et al. and Shi et al. reveal that certain gliomas rely on the de novo synthesis of pyrimidines. These studies go on to demonstrate the effectiveness of brain-penetrant inhibitors of de novo pyrimidine synthesis in preclinical models of glioma.
